최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국수산과학회지 = Korean journal of fisheries and aquatic sciences, v.49 no.6, 2016년, pp.807 - 814
임미진 (국립해양생물자원관 천연물연구팀) , 이대성 (국립해양생물자원관 천연물연구팀) , 최그레이스 (국립해양생물자원관 천연물연구팀) , 이정민 (국립해양생물자원관 천연물연구팀) , 최일환 (인제대학교 의과대학 미생물학교실)
Fucoidan, one of the dominant sulfated polysaccharides extracted from brown seaweed, possesses a wide range of biological activities. Transforming growth
핵심어 | 질문 | 논문에서 추출한 답변 |
---|---|---|
특발폐섬유증이란? | 특발폐섬유증(idiopathic pulmonary fibrosis, IPF)은 아직 밝혀지지 않은 원인에 의해 폐포, 모세 혈관, 세기관지, 림프관 등 간질 조직에 염증이 발생하여 점차 조직이 딱딱하게 굳어지는 섬유화가 특징적인 통상성 간질성 폐렴(usualinterstitial pneumonia, UIP)을 보이는 질환이다(King et al., 2000). | |
Fucoidan은 어디서 얻어지는가? | Fucoidan은 미역, 톳, 감태, 대황, 다시마 등의 갈조류의 세포벽 구성 성분으로부터 분리한 고분자 황산화다당류(sulfated polysaccharides)로서 점성이 낮고 용해성이 우수한 특징을 가지고 있다(Park et al., 2007). | |
Fucoidan은 어떤 면역세포에 대해 면역조절기능이 있는가? | , 2015). 또한 림프구, 대식세포, 자연살해세포, 수지상세포와 같은 다양한 면역세포에 대해 면역조절기능을 가지고 있는 것으로 알려져 있다(Jin et al., 2014). |
Ahluwalia N, Shea BS and Tager AM. 2014. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med 190, 867-878. http://dx.doi.org/10.1164/rccm.201403-0509PP.
Ahmed AB, Adel M, Karimi P and Peidayesh M. 2014. Pharmaceutical, cosmeceutical, and traditional applications of marine carbohydrates. Adv Food Nutr Res 73, 197-222. http://dx.doi.org/10.1016/B978-0-12-800268-1.00010-X.
Antoniou KM, Margaritopoulos GA and Siafakas NM. 2013. Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. Eur Respir Rev 22, 281-291. http://dx.doi.org/10.1183/09059180.00002113.
Blobe GC, Schiemann WP and Lodish HF. 2000. Role of transforming growth factor beta in human disease. N Engl J Med 342, 1350-1358. http://dx.doi.org/10.1056/NEJM200005043421807.
Broekelmann TJ, Limper AH, Colby TV and McDonald JA. 1991. Transforming growth factor beta 1 is present at sites of extracellular matrix gene expression in human pulmonary fibrosis. Proc Natl Acad Sci U S A 88, 6642-6646.
Camelo A, Dunmore R, Sleeman MA and Clarke DL. 2014. The epithelium in idiopathic pulmonary fibrosis: breaking thebarrier. Front Pharmacol 4, 173. http://dx.doi.org/10.3389/fphar.2013.00173.
Cho Y, Yoon JH, Yoo JJ, Lee M, Lee DH, Cho EJ, Lee JH, Yu SJ, Kim YJ and Kim CY. 2015. Fucoidan protects hepatocytes from apoptosis and inhibits invasion of hepatocellular carcinoma by up-regulating p42/44 MAPK-dependent NDRG-1/CAP43. Acta Pharm Sin B 5, 544-553. http://dx.doi.org/10.1016/j.apsb.2015.09.004.
Coker RK, Laurent GJ, Shahzeidi S, HernandezRodriguez NA, Pantelidis P, du Bois RM, Jeffery PK and McAnulty RJ. 1996. Diverse cellular $TGF-{\beta}1\;and\;TGF-{\beta}3$ gene expression in normal human and murine lung. Eur Respir 9, 2501-2507.
Cottin V. 2016. Idiopathic interstitial pneumonias with connectivetissue diseases features: A review. Respirology 21, 245-258. http://dx.doi.org/10.1111/resp.12588.
Fries KM, Felch ME and Phipps RP. 1994. Interleukin-6 is an autocrine growth factor for murine lung fibroblast subsets. Am J Respir Cell Mol Biol 11, 552-560. http://dx.doi.org/10.1165/ajrcmb.11.5.7946384.
Guo B, Inoki K, Isono M, Mori H, Kanasaki K, Sugimoto T, Akiba S, Sato T, Yang B, Kikkawa R, Kashiwagi A, Haneda M and Koya D. 2005. MAPK/AP-1-dependent regulation of PAI-1 gene expression by TGF-beta in rat mesangial cells. Kidney Int 68, 972-984. http://dx.doi.org/10.1111/j.1523-1755.2005.00491.x.
Hinz B. 2007. Formation and function of the myofibroblast during tissue repair. J Invest Dermatol 127, 526-537. http://dx.doi.org/10.1038/sj.jid.5700613.
Hu B, Wu Z and Phan SH. 2003. Smad3 mediates transforming growth factor- ${\beta}$ -induced ${\alpha}$ -smooth muscle actin expression. Am J Respir Cell MolBiol 29, 397-404. http://dx.doi.org/10.1165/rcmb.2003-0063OC.
Jin JO, Zhang W, Du JY, Wong KW, Oda T and Yu Q. 2014. Fucoidan can function as an adjuvant in vivo to enhance dendritic cell maturation and function and promote antigenspecific T cell immune responses. PLoS One 9, e99396. http://dx.doi.org/10.1371/journal.pone.0099396.
Khalil N, O'Connor RN, Unruh HW, Warren PW, Flanders KC, Kemp A, Bereznay OH and Greenberg AH. 1991. Increased production and immunohistochemical localization of transforming growth factor-beta in idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol 5, 155-162.
King TE, Costabel U, Cordier JF, Dopoco GA, Bois RM, Lynch D, Myers J, Panos R, Raghu G, Schwartz D and Smith CM. 2000. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161, 646-664. http://dx.doi.org/10.1164/ajrccm.161.2.ats3-00.
King TE Jr, Pardo A and Selman M. 2011. Idiopathic pulmonary fibrosis. Lancet 378, 1949-1961. http://dx.doi.org/10.1016/S0140-6736(11)60052-4.
Kuznetsova TA, Besednova NN, Somova LM and Plekhova NG. 2014. Fucoidan extracted from Fucus evanescens prevents endotoxin-induced damage in a mouse model of endotoxemia. Mar Drugs 12, 886-898. http://dx.doi.org/10.3390/md12020886.
Leask A and Abraham DJ. 2004. TGF-beta signaling and the fibrotic response. FASEB J 18, 816-827. http://dx.doi.org/10.1096/fj.03-1273rev.
Luo F, Zhuang Y, Sides MD, Sanchez CG, Shan B, White ES and Lasky JA. 2014. Arsenic trioxide inhibits transforming growth factor- ${\beta}1$ -induced fibroblast to myofibroblast differentiation in vitro and bleomycin induced lung fibrosis in vivo. Respir Res 15,51. http://dx.doi.org/10.1186/1465-9921-15-51.
Moore MW and Herzog EL. 2013. Regulation and Relevance of Myofibroblast Responses in Idiopathic Pulmonary Fibrosis. Curr Pathobiol Rep 1, 199-208. http://dx.doi.org/10.1007/s40139-013-0017-8.
O'Leary R, Rerek M and Wood EJ. 2004. Fucoidan modulates the effect of transforming growth factor (TGF)-beta1 on fibroblast proliferation and wound repopulation in in vitro models of dermal wound repair. Biol Pharm Bull 27, 266-270.
Pan R, Zhang Y, Zang B, Tan L and Jin M. 2016. Hydroxysafflor yellow A inhibits TGF- ${\beta}1$ -induced activation of human fetal lung fibroblasts in vitro. J Pharm Pharmacol 68, 1320-1330. http://dx.doi.org/10.1111/jphp.12596.
Park KY, Back JH, Hur W and Lee SY. 2007. In vitro glucose and bile acid retardation effect of fucoidan from Laminaria japonica. Kor J Biotechnol Bioeng 4, 265-269.
Pedroza M, Schneider DJ, Karmouty-Quintana H, Coote J, Shaw S, Corrigan R, Molina JG, Alcorn JL, Galas D, Gelinas R and Blackburn MR. 2011. Interleukin-6 contributes to inflammation and remodeling in a model of adenosine mediated lung injury. PLoS ONE 6, e22667. http://dx.doi.org/10.1371/journal.pone.0022667.
Raghu G, Weycker D, Edelsberg J, Bradford WZ and Oster G. 2006. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174, 810-816. http://dx.doi.org/10.1164/rccm.200602-163OC.
Tanaka K, Ishihara T, Azuma A, Kudoh S, Ebina M, Nukiwa T, Sugiyama Y, Tasaka Y, Namba T, Ishihara T, Sato K, Mizushima Y and Mizushima T. 2010. Therapeutic effect of lecithinized superoxide dismutase on bleomycininduced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 298, L348-L360. http://dx.doi.org/10.1152/ajplung.00289.2009.
Tomasek JJ, Gabbiani G, Hinz B, Chaponnier C and Brown RA. 2002. Myofibroblasts and mechano-regulation of connective tissue remodelling. Nat Rev Mol Cell Biol 3, 349-363. http://dx.doi.org/10.1038/nrm809.
Wang Q, Wang Y, Hyde DM, Gotwals PJ, Koteliansky VE, Ryan ST and Giri SN. 1999. Reduction of bleomycin induced lung fibrosis by transforming growth factor beta solublereceptor in hamsters. Thorax 54, 805-812.
Park KH, Cho EH, Kim NC and Chae HJ. 2010. Production of Fucoidan Using Marine Algae. KSBB Journal 25, 223-229.
해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.